GlassScriptPhysician profile
Sanah Rahman
NPI 1972387371
$2,297.66
in general payments reported to CMS, 2019-2025
33 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $679 · 2024: $1,443 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,281 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,280.94 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $319.44 | 2023-2025 | |
| Ucb, INC. | $317.99 | 2023-2024 | Rystiggo, Briviact |
| Pfizer INC. | $215.55 | 2024-2025 | |
| Sk Life Science, INC. | $154.99 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $146.62 | 2023-2025 | Ingrezza, Ongentys |
| Acorda Therapeutics, INC | $97.18 | 2023-2024 | Inbrija |
| Lundbeck LLC | $82.49 | 2023-2025 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $82.15 | 2023-2025 | Nuedexta, Rexulti |
| Alexion Pharmaceuticals, INC. | $79.59 | 2023-2024 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $70.65 | 2024 | Zeposia |
| Novartis Pharmaceuticals Corporation | $70.15 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $68.21 | 2023-2024 | Aptiom |
| Catalyst Pharmaceuticals, INC. | $51.72 | 2024 | |
| Eisai INC. | $51.07 | 2024-2025 | |
| Tanabe Pharma America, INC. | $49.22 | 2023-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $48.52 | 2023-2024 | Emgality, Reyvow |
| Mdd US Operations, LLC | $38.20 | 2024 | Gocovri |
| Octapharma USA, INC. | $37.27 | 2024 | Panzyga |
| Azurity Pharmaceuticals, INC. | $30.62 | 2024 | Horizant |
| Ge Healthcare | $27.72 | 2025 | |
| Amgen INC. | $26.94 | 2024 | Uplizna |
| Horizon Therapeutics Plc | $26.77 | 2023 | Uplizna |
| Argenx US, INC. | $23.48 | 2024 | Vyvgart Hytrulo |
| Si-Bone, INC. | $22.04 | 2024 | |
| Xeris Pharmaceuticals, INC. | $22.03 | 2024 | Keveyis |
| Teva Pharmaceuticals USA, INC. | $20.37 | 2024 | Austedo Xr |
| Grifols USA, LLC | $20.20 | 2024 | Gamunex-C |
| Jazz Pharmaceuticals INC. | $18.40 | 2024 | |
| Amneal Pharmaceuticals LLC | $18.38 | 2024 | Rytary |
| Biogen, INC. | $16.46 | 2024 | Skyclarys |
| Acadia Pharmaceuticals INC | $15.93 | 2024 | Nuplazid |
| Kyowa Kirin, INC. | $14.13 | 2024 | Nourianz |
| Boston Scientific Corporation | $13.18 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanah Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.